XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
FDA investigators closed an 11-day inspection of Catalent Indiana LLC's sterile injectable facility in Bloomington, Indiana, on April 24, 2026, documenting eight inspectional observations spanning environmental monitoring, aseptic process validation, visual inspection, and investigation
View details →
The Quality Overall Summary is the first CMC document a regulatory reviewer reads. It sets their expectations, frames the complexity of the submission, and either reassures them that the applicant understands their own data
View details →
FDA investigators are trained to look for what is missing from your data records before they look at what is present — and the deletion of failed runs, rejected results, or inconvenient data points
View details →
"When a regulatory reviewer opens the QOS drug product section, they are looking for three things: that you understand why your formulation is designed the way it is, that your analytical methods are capable
View details →
Most pharmaceutical companies operating in both the US and EU believe that if their electronic systems comply with 21 CFR Part 11, they also satisfy EU Annex 11 — this assumption is the source
View details →
The average NDA CMC review cycle includes at least one round of deficiencies. The average ANDA review includes two. The companies that convert deficiency letters into expedited approvals are not those with the fewest
View details →
An audit trail that exists but is never reviewed is not a compliance control — it is a liability waiting to be discovered by an FDA investigator who will review it more thoroughly in
View details →
The approval of a new drug application is not the end of CMC regulatory work — it is the beginning of a decades-long change management challenge. The most expensive regulatory decisions in pharmaceutical product
View details →
The most dangerous statement in pharmaceutical quality is "the result was retested and passed" — because that sentence, without the three-phase investigation framework that FDA requires before any retest is scientifically valid, is the
View details →
"CMC is holding up the NDA." This sentence is spoken in development teams every year — about programs where clinical and non-clinical development proceeded at the expected pace, but the CMC package was developed
View details →
Most 483 responses fail not because the company failed to address the observation — but because the response addressed the symptom FDA described while leaving the quality system gap that caused it fully intact.
View details →
A recurring CMC review issue is not the absence of process information, but the absence of a coherent evidentiary bridge between critical-step controls, process validation or evaluation, and the development knowledge used to justify
View details →
A data integrity Warning Letter is not a documentation problem — it is a credibility crisis, and the difference between companies that recover in 18 months and those that face import alerts is whether
View details →
A structural-elucidation package is not simply a collection of spectra. It is an integrated identity argument showing that the material described in the dossier is the drug substance intended for clinical and commercial use.
View details →
The apparent pKa of the ionizable lipid component is not a routine physicochemical descriptor. It is the master variable from which endosomal escape efficiency, organ biodistribution, immune activation profile, and systemic tolerability all emerge
View details →
"ICH Q3A(R2) sets reporting, identification, and qualification thresholds for drug substance impurities that have been in force since 2006. Nearly two decades later, the most common impurity-related deficiency FDA issues is not a failure
View details →
The CMC package FDA receives is not evaluated solely on the science it contains — it is evaluated on whether the scientific narrative is coherent, internally consistent, and written in a way that allows
View details →
This distinction is not semantic. It is the difference between a response that closes a Warning Letter in a single review cycle and one that triggers an escalation path ending in an import alert,
View details →